Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Mitigating the Spread of Hospital-Acquired Infections

During the global spread of the novel coronavirus, the ensuing COVID-19 pandemic and, now, efforts to engage in reopening, much has been said about strategies aimed at helping control infection in our daily lives. However, what about in the very facilities treating not only patients with COVID-19, but those with other conditions? Hospital-acquired infections, those…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

During the global spread of the novel coronavirus, the ensuing COVID-19 pandemic and, now, efforts to engage in reopening, much has been said about strategies aimed at helping control infection in our daily lives.

However, what about in the very facilities treating not only patients with COVID-19, but those with other conditions?

Hospital-acquired infections, those acquired in the hospital or place of treatment as opposed to prior to arriving at those facilities, can throw a major wrench in practices’ and hospitals’ ability to effectively care for patients.

Vioguard Vice President of Sales and Marketing, Mark Beeston, joined host Daniel Litwin to outline the company’s mission – improving infection control and helping curtail hospital-acquired infections – and how it goes about achieving those goals.

“[COVID-19] heightened awareness in the healthcare space,” Beeston said. “There were processes in place, already, but those processes have now been enhanced. You’re seeing more diligence in areas that are really hypersensitive.”

This heightened diligence has particularly affected places like newborn ICUs and operating rooms, and even families of patients are being more thoroughly screened and sanitized. It’s also increased attention on aspects of exposure that might have previously been overlooked, such as visitor cellphones.

Established in 2008, Vioguard develops solutions that utilize ultraviolet light to aid in sanitization efforts, working to provide effective infection control measures that don’t interfere with productivity or accuracy.

Litwin and Beeston explored how and why healthcare professionals might spread infection, the current state of prevention, and immediate and long-term strategies for avoiding hospital-acquired infections.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512